Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria:
- Documented initial diagnosis of multiple myeloma according to international myeloma
working group (IMWG) diagnostic criteria
- Part 3: Measurable disease cohort A, cohort B, cohort C, and cohort D: multiple
myeloma must be measurable by central laboratory assessment
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- Women of childbearing potential must have a negative pregnancy test at screening and
prior to the first dose of study drug using a highly sensitive pregnancy test either
serum (beta human chorionic gonadotropin [hCG]) or urine
- Willing and able to adhere to the prohibitions and restrictions specified in this
protocol
Exclusion Criteria:
- Part 3 only: Cohort A and Cohort C only: exposed to a CAR-T or T cell redirection
therapy at any time. Cohort B and Cohort D: T cell redirection therapy within 3
months
- Toxicities from previous anticancer therapies should have resolved to baseline
levels or to Grade 1 or less except for alopecia or peripheral neuropathy
- Received a cumulative dose of corticosteroids equivalent to >= 140 milligram (mg) of
prednisone within the 14-day period before the first dose of study drug (does not
include pretreatment medication)
- Stroke or seizure within 6 months prior to signing the informed consent form (ICF)